Clincosm LogoSign in Get a demo

Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus

Sponsor
Riphah International University (Other)
Overall Status
Completed
CT.gov ID
NCT04924777
Collaborator
(none)
48
Enrollment
1
Location
3
Arms
4
Actual Duration (Months)
12.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study design is to determine the effectiveness of moderate physical activity on g;lycemic control in type 2 diabetes mellitus.

Condition or Disease Intervention/Treatment Phase
  • Other: Brisk Walk
  • Other: Strength training
  • Other: Aerobic Exercises
 N/A

Detailed Description

To the best of authors knowledge so far the studies have been conducted on different modes of moderate physical activity on glycemic control in type 2 diabetes, current study goal is to evaluate which mode of moderate physical activity has more significant result on glycemic control in type 2 diabetes and is sustainable in Pakistani society according to the socioeconomic status and cost effectiveness of the modes of moderate physical activity.

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Effects of Moderate Physical Activity on Glycemic Control in Type 2 Diabetes Mellitus
Actual Study Start Date :
Apr 1, 2021
Actual Primary Completion Date :
Jul 31, 2021
Actual Study Completion Date :
Jul 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brisk walk

Other: Brisk Walk
1-Brisk walk for 30 minutes 2-5 days a week 3-3months

Other: Strength training
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

Other: Aerobic Exercises
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
Experimental: Aerobic Training

Other: Brisk Walk
1-Brisk walk for 30 minutes 2-5 days a week 3-3months

Other: Strength training
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

Other: Aerobic Exercises
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
Experimental: Strength Training

Other: Brisk Walk
1-Brisk walk for 30 minutes 2-5 days a week 3-3months

Other: Strength training
1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months

Other: Aerobic Exercises
1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months

Outcome Measures

Primary Outcome Measures

  1. HbA1c Levels [3 months]

    Reduction in HbA1c levels

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Participants falling in this category would be recruited into the study.

  • Male/female

  • Diabetic type 2 patients

  • Age: 30-70 years

  • BMI >25

  • Overweight

  • Fat % in male> 25

  • Fat % in female >35

  • HbA1c level more than 48mmol/mol or >6.5%

  • Fasting Plasma Glucose level >126 mg/dl (7.0 mmol/l)

  • Random Plasma glucose level >200 mg/dl (11.1 mmol/l)

  • Physically active ( have no mobility problems)

Exclusion Criteria:

  • Participant failing to fall in this category would be excluded of the study.

  • Type 1 diabetes

  • Insulin dependant type 2 diabetes

  • Gestational Diabetes

  • Hypertension

  • Cigarette smoking

  • Cardiovascular Disease

  • Cerebrovascular disease

  • Cardiopulmonary Disorders

  • Cognition Problems

  • Peripheral Artery Disease

  • Dyslipidemia

  • Proliferative or preproliferative retinopathy

  • Nephropathy

  • Neuropathy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Riphah Rehabilitation Center Islamabad Pakistan 44000

Sponsors and Collaborators

  • Riphah International University

Investigators

  • Principal Investigator: Waqar Ahmad Awan, Riphah International University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Riphah International University
ClinicalTrials.gov Identifier:
NCT04924777
Other Study ID Numbers:
  • REC/0929 Zainab Qadri
First Posted:
Jun 14, 2021
Last Update Posted:
Nov 26, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2

Study Results

No Results Posted as of Nov 26, 2021